Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of DWP14012 and NSAIDs in Healthy Male Volunteers
NCT04490434Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 16 and Area Under the Curve Over Dosing Interval at Steady State at Day 16. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04490434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490434.